The new SPAC intends to focus its search on the global biopharma or technology-enabled business-to-consumer (“B2C”) industries. TLGY is led by Founder, Chairman, and Chief Executive Officer Jin-Goon Kim, Co-President Theron E. Odlaug, and Co-President and Chief Financial Officer Steven Norman.
Total SPAC deal count for 2021 year-to-date is now 563. This offering is expected to close on Friday, December 3.
Mizuho Securities is acting as the sole bookrunner for the offering, and Robert W. Baird & Co. Incorporated is acting as lead manager for the offering. Cleary Gottlieb Steen & Hamilton LLP is serving as Issuer’s Counsel with Greenberg Traurig, P.A. serving as Underwriter’s Counsel. Marcum Bernstein & Pinchuk LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.